Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
Selective inhibition of the BCR-ABL tyrosine kinase by imatinib (STI571, Glivec/Gleevec) is a promising new therapeutic strategy in patients with chronic myelogenous leukemia (CML). Despite significant hematologic and cytogenetic responses, resistance occurs, particularly in patients with advanced d...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
28 October 2002
|
| In: |
Leukemia
Year: 2002, Jahrgang: 16, Heft: 11, Pages: 2190-2196 |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/sj.leu.2402741 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/sj.leu.2402741 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/2402741 
|
| Verfasserangaben: | A. Hochhaus, S. Kreil, A.S. Corbin, P. La Rosée, M.C. Müller, T. Lahaye, B. Hanfstein, C. Schoch, N.C.P. Cross, U. Berger, H. Gschaidmeier, B.J. Druker and R. Hehlmann |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1801851778 | ||
| 003 | DE-627 | ||
| 005 | 20230426073537.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220516s2002 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/sj.leu.2402741 |2 doi | |
| 035 | |a (DE-627)1801851778 | ||
| 035 | |a (DE-599)KXP1801851778 | ||
| 035 | |a (OCoLC)1341460116 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hochhaus, Andreas |d 1959- |e VerfasserIn |0 (DE-588)1107039339 |0 (DE-627)863321976 |0 (DE-576)474976130 |4 aut | |
| 245 | 1 | 0 | |a Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy |c A. Hochhaus, S. Kreil, A.S. Corbin, P. La Rosée, M.C. Müller, T. Lahaye, B. Hanfstein, C. Schoch, N.C.P. Cross, U. Berger, H. Gschaidmeier, B.J. Druker and R. Hehlmann |
| 264 | 1 | |c 28 October 2002 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 16.05.2022 | ||
| 520 | |a Selective inhibition of the BCR-ABL tyrosine kinase by imatinib (STI571, Glivec/Gleevec) is a promising new therapeutic strategy in patients with chronic myelogenous leukemia (CML). Despite significant hematologic and cytogenetic responses, resistance occurs, particularly in patients with advanced disease. We sought to determine the underlying mechanisms. Sixty-six patients with CML in myeloid blast crisis (n = 33), lymphoid blast crisis (n = 2), accelerated phase (n = 16), chronic phase (n = 13), and BCR-ABL-positive acute lymphoblastic leukemia (n = 2) resistant to imatinib were investigated. Median duration of imatinib therapy was 148 days (range 6-882). Patients were evaluated for genomic amplification of BCR-ABL, overexpression of BCR-ABL transcripts, clonal karyotypic evolution, and mutations of the imatinib binding site in the BCR-ABL tyrosine kinase domain. Results were as follows: (1) Median levels of BCR-ABL transcripts, were not significantly changed at the time of resistance but 7/55 patients showed a >10-fold increase in BCR-ABL levels; (2) genomic amplification of BCR-ABL was found in 2/32 patients evaluated by fluorescence in situ hybridization; (3) additional chromosomal aberrations were observed in 19/36 patients; (4) point mutations of the ABL tyrosine kinase domain resulting in reactivation of the BCR-ABL tyrosine kinase were detected in 23/66 patients. In conclusion, although the heterogeneous development of imatinib resistance is challenging, the fact that BCR-ABL is active in many resistant patients suggests that the chimeric oncoprotein remains a good therapeutic target. However, patients with clonal evolution are more likely to have BCR-ABL-independent mechanisms of resistance. The observations warrant trials combining imatinib with other agents. | ||
| 650 | 4 | |a Cancer Research | |
| 650 | 4 | |a general | |
| 650 | 4 | |a Hematology | |
| 650 | 4 | |a Intensive / Critical Care Medicine | |
| 650 | 4 | |a Internal Medicine | |
| 650 | 4 | |a Medicine/Public Health | |
| 650 | 4 | |a Oncology | |
| 700 | 1 | |a Kreil, Sebastian |d 1972- |e VerfasserIn |0 (DE-588)1072240564 |0 (DE-627)827077742 |0 (DE-576)433714093 |4 aut | |
| 700 | 1 | |a Corbin, A. S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a La Rosée, Paul |d 1969- |e VerfasserIn |0 (DE-588)122116674 |0 (DE-627)081745966 |0 (DE-576)293100357 |4 aut | |
| 700 | 1 | |a Müller, Martin Christian |d 1972- |e VerfasserIn |0 (DE-588)121360296 |0 (DE-627)705409236 |0 (DE-576)181482819 |4 aut | |
| 700 | 1 | |a Lahaye, T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hanfstein, Benjamin |d 1971- |e VerfasserIn |0 (DE-588)143353519 |0 (DE-627)645128228 |0 (DE-576)336605587 |4 aut | |
| 700 | 1 | |a Schoch, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cross, N. C. P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Berger, Ute |e VerfasserIn |0 (DE-588)1255399929 |0 (DE-627)1799635341 |4 aut | |
| 700 | 1 | |a Gschaidmeier, Harald |d 1965- |e VerfasserIn |0 (DE-588)172811074 |0 (DE-627)697741354 |0 (DE-576)133667324 |4 aut | |
| 700 | 1 | |a Druker, B. J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hehlmann, Rüdiger |d 1941- |e VerfasserIn |0 (DE-588)1037003489 |0 (DE-627)751737879 |0 (DE-576)390939463 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d London : Springer Nature, 1997 |g 16(2002), 11, Seite 2190-2196 |h Online-Ressource |w (DE-627)32046699X |w (DE-600)2008023-2 |w (DE-576)094139733 |x 1476-5551 |7 nnas |a Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy |
| 773 | 1 | 8 | |g volume:16 |g year:2002 |g number:11 |g pages:2190-2196 |g extent:7 |a Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy |
| 856 | 4 | 0 | |u https://doi.org/10.1038/sj.leu.2402741 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/2402741 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220516 | ||
| 993 | |a Article | ||
| 994 | |a 2002 | ||
| 998 | |g 1037003489 |a Hehlmann, Rüdiger |m 1037003489:Hehlmann, Rüdiger |d 60000 |d 61200 |e 60000PH1037003489 |e 61200PH1037003489 |k 0/60000/ |k 1/60000/61200/ |p 13 |y j | ||
| 998 | |g 1255399929 |a Berger, Ute |m 1255399929:Berger, Ute |d 60000 |d 61200 |e 60000PB1255399929 |e 61200PB1255399929 |k 0/60000/ |k 1/60000/61200/ |p 10 | ||
| 998 | |g 143353519 |a Hanfstein, Benjamin |m 143353519:Hanfstein, Benjamin |d 60000 |d 61200 |e 60000PH143353519 |e 61200PH143353519 |k 0/60000/ |k 1/60000/61200/ |p 7 | ||
| 998 | |g 121360296 |a Müller, Martin Christian |m 121360296:Müller, Martin Christian |d 60000 |d 61200 |e 60000PM121360296 |e 61200PM121360296 |k 0/60000/ |k 1/60000/61200/ |p 5 | ||
| 998 | |g 122116674 |a La Rosée, Paul |m 122116674:La Rosée, Paul |d 60000 |d 61200 |e 60000PL122116674 |e 61200PL122116674 |k 0/60000/ |k 1/60000/61200/ |p 4 | ||
| 998 | |g 1072240564 |a Kreil, Sebastian |m 1072240564:Kreil, Sebastian |d 60000 |d 61200 |e 60000PK1072240564 |e 61200PK1072240564 |k 0/60000/ |k 1/60000/61200/ |p 2 | ||
| 998 | |g 1107039339 |a Hochhaus, Andreas |m 1107039339:Hochhaus, Andreas |d 60000 |d 61200 |e 60000PH1107039339 |e 61200PH1107039339 |k 0/60000/ |k 1/60000/61200/ |p 1 |x j | ||
| 999 | |a KXP-PPN1801851778 |e 4134459605 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"display":"Hochhaus, Andreas","family":"Hochhaus","role":"aut","given":"Andreas"},{"given":"Sebastian","role":"aut","family":"Kreil","display":"Kreil, Sebastian"},{"given":"A. S.","role":"aut","display":"Corbin, A. S.","family":"Corbin"},{"family":"La Rosée","display":"La Rosée, Paul","given":"Paul","role":"aut"},{"given":"Martin Christian","role":"aut","display":"Müller, Martin Christian","family":"Müller"},{"family":"Lahaye","display":"Lahaye, T.","given":"T.","role":"aut"},{"family":"Hanfstein","display":"Hanfstein, Benjamin","role":"aut","given":"Benjamin"},{"role":"aut","given":"C.","display":"Schoch, C.","family":"Schoch"},{"family":"Cross","display":"Cross, N. C. P.","role":"aut","given":"N. C. P."},{"display":"Berger, Ute","family":"Berger","role":"aut","given":"Ute"},{"display":"Gschaidmeier, Harald","family":"Gschaidmeier","given":"Harald","role":"aut"},{"display":"Druker, B. J.","family":"Druker","role":"aut","given":"B. J."},{"family":"Hehlmann","display":"Hehlmann, Rüdiger","role":"aut","given":"Rüdiger"}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2002","dateIssuedDisp":"28 October 2002"}],"note":["Gesehen am 16.05.2022"],"title":[{"title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","title_sort":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy"}],"id":{"doi":["10.1038/sj.leu.2402741"],"eki":["1801851778"]},"name":{"displayForm":["A. Hochhaus, S. Kreil, A.S. Corbin, P. La Rosée, M.C. Müller, T. Lahaye, B. Hanfstein, C. Schoch, N.C.P. Cross, U. Berger, H. Gschaidmeier, B.J. Druker and R. Hehlmann"]},"physDesc":[{"extent":"7 S."}],"recId":"1801851778","relHost":[{"id":{"eki":["32046699X"],"issn":["1476-5551"],"zdb":["2008023-2"]},"recId":"32046699X","physDesc":[{"extent":"Online-Ressource"}],"disp":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapyLeukemia","type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title_sort":"Leukemia","subtitle":"normal and malignant hemopoiesis ; a peer-reviewed journal","title":"Leukemia"}],"note":["Gesehen am 15.03.04"],"origin":[{"publisher":"Springer Nature ; Stockton Press ; Nature Publ. Group","dateIssuedKey":"1997","dateIssuedDisp":"1997-","publisherPlace":"London ; Basingstoke [u.a.] ; Basingstoke"}],"pubHistory":["Nachgewiesen 11.1997 -"],"part":{"text":"16(2002), 11, Seite 2190-2196","issue":"11","year":"2002","pages":"2190-2196","extent":"7","volume":"16"},"language":["eng"]}]} | ||
| SRT | |a HOCHHAUSANMOLECULARA2820 | ||